0 results available. Select is focused ,type to refine list, press Down to open the menu,
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the...
The following section summarizes insights on Roche Holding AG Participation's Net Income to Stockholders Margin:
We've identified the following companies as similar to Roche Holding AG Participation because they operate in a related industry or sector. We also considered size, growth, and various financial metrics to narrow down the list to the ones listed below.
| Name | Ticker | Net Income to Stockholders Margin |
|---|---|---|
| Bayer AG | SWX:BAYN | -5.5% |
| GlaxoSmithKline PLC | BRSE:001102657 | 8.2% |
| Healthcare | SECTOR:HLTH.CH | 8.8% |
| Lonza Group AG | SWX:LONN | 9.7% |
| Sanofi SA | ENXTPA:SAN | 12.6% |
| AstraZeneca PLC | BRSE:000982352 | 13.0% |
| Merck KGaA | BRSE:MER | 13.1% |
| Roche Holding AG Participation | LSE:0QOK | 13.3% |
| H. Lundbeck A/S | DB:LDBB | 14.3% |
| Johnson & Johnson | BRSE:000943981 | 15.8% |
| Merck & Co., Inc. | BRSE:010683053 | 26.7% |
| Novo Nordisk A/S | BRSE:NOVOB | 34.8% |
To view the full list of supported financial metrics please see Complete Metrics Listing.
Metrics similar to Net Income to Stockholders Margin in the efficiency category include:
A ratio that measures the amount of profit that stockholders earn on each dollar of revenue earned by the firm.
The net income to stockholders margin measures a company’s net income to stockholders as a percentage of the revenue. The formula to calculate net income to stockholders margin and an example calculation for Roche’s trailing twelve months is outlined below:
Net Income to Stockholders Margin = Net Income to Stockholders / Total Revenue
13.3% = 8.277 B / 62.395 B
The tables below summarizes Roche’s performance over the last five years:
| Fiscal Year | Net Income to Stockholders | Revenue | Margin |
|---|---|---|---|
| 2020-12-31 | 14.295 B | 60.343 B | 23.7% |
| 2021-12-31 | 13.93 B | 65.85 B | 21.2% |
| 2022-12-31 | 12.421 B | 65.814 B | 18.9% |
| 2023-12-31 | 11.498 B | 60.441 B | 19.0% |
| 2024-12-31 | 8.277 B | 62.395 B | 13.3% |
The tables below summarizes Roche’s performance over the last four quarters:
| Quarter Ending | Net Income to Stockholders | Revenue | Margin |
|---|---|---|---|
| 2024-03-31 | 3.129 B | 15.378 B | 20.3% |
| 2024-06-30 | 3.129 B | 15.378 B | 20.3% |
| 2024-09-30 | 1.01 B | 15.819 B | 6.4% |
| 2024-12-31 | 1.01 B | 15.819 B | 6.4% |
You can read more about Net Income to Stockholders here.
The chart above depicts the distribution of net income to stockholders margin for companies operating in the Healthcare sector in the Developed economic region. Over 2,005 companies were considered in this analysis, and 1,930 had meaningful values. The average net income to stockholders margin of companies in the sector is -1,145.6% with a standard deviation of 4,363.4%.
Roche Holding AG Participation's Net Income to Stockholders Margin of 13.3% ranks in the 88.9% percentile for the sector. The following table provides additional summary stats:
| Economic Risk Region | Developed |
| Total Constituents | 2,010 |
| Included Constituents | 1,930 |
| Min | -48,464.0% |
| Max | 115.8% |
| Median | -24.8% |
| Mean | -1,145.6% |
| Standard Deviation | 4,363.4% |
You can find companies with similar net income to stockholders margin using this stock screener.